David M. Stresser

3.1k total citations
54 papers, 2.5k citations indexed

About

David M. Stresser is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, David M. Stresser has authored 54 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pharmacology, 18 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in David M. Stresser's work include Pharmacogenetics and Drug Metabolism (32 papers), Drug Transport and Resistance Mechanisms (17 papers) and Eicosanoids and Hypertension Pharmacology (10 papers). David M. Stresser is often cited by papers focused on Pharmacogenetics and Drug Metabolism (32 papers), Drug Transport and Resistance Mechanisms (17 papers) and Eicosanoids and Hypertension Pharmacology (10 papers). David M. Stresser collaborates with scholars based in United States, United Kingdom and Singapore. David M. Stresser's co-authors include Charles L. Crespi, David Kupfer, Stephanie D. Turner, Vaughn P. Miller, G.S. Bailey, Andrew P. Blanchard, D E Williams, Andre Dandeneau, Shangara S. Dehal and J. Andrew Williams and has published in prestigious journals such as Biochemistry, Analytical Biochemistry and Annals of the New York Academy of Sciences.

In The Last Decade

David M. Stresser

53 papers receiving 2.4k citations

Peers

Countries citing papers authored by David M. Stresser

Since Specialization

Citations

This map shows the geographic impact of David M. Stresser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Stresser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Stresser more than expected).

Fields of papers citing papers by David M. Stresser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Stresser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Stresser. The network helps show where David M. Stresser may publish in the future.

Co-authorship network of co-authors of David M. Stresser

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Stresser. A scholar is included among the top collaborators of David M. Stresser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Stresser. David M. Stresser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	High-Throughput SFC-MS/MS Method to Measure EPSA and Predict Human Permeability 2024 ·Journal of Medicinal Chemistry ·(unknown), Edward Price, Mei Feng, (unknown), Stella Z. Doktor, David M. Stresser, Estelle M. Maes, Qin Ji, Gary J. Jenkins	6
2	Clearance prediction with three novel plated human hepatocyte models compared to conventional suspension assays: Assessment with 50 compounds and multiple donors 2024 ·Drug Metabolism and Disposition ·(unknown), J Schulz, (unknown), (unknown), (unknown), J. Cory Kalvass, David M. Stresser	0
3	Broad Application of CYP3A4 Liquid Chromatography-Mass Spectrometry Protein Quantification in Hepatocyte Cytochrome P450 Induction Assays Identifies Nonuniformity in mRNA and Protein Induction Responses 2021 ·Drug Metabolism and Disposition ·John P. Savaryn, Jun Sun, Junli Ma, Gary J. Jenkins, David M. Stresser	14
4	Metabolism and Disposition of a Novel Selective α7 Neuronal Acetylcholine Receptor Agonist ABT-126 in Humans: Characterization of the Major Roles for Flavin-Containing Monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in Catalysis 2018 ·Drug Metabolism and Disposition ·Hong Liu, David M. Stresser, (unknown), Xiaofeng Li, Mohamed I. A. Othman, (unknown), Michael R. Schrimpf, Jens Sydor, Anthony Lee	5
5	Selective Time- and NADPH-Dependent Inhibition of Human CYP2E1 by Clomethiazole 2016 ·Drug Metabolism and Disposition ·David M. Stresser, Elke S. Perloff, (unknown), (unknown), Shangara S. Dehal, (unknown), (unknown), Eric T. Gangl	19
6	Evaluation of Calibration Curve–Based Approaches to Predict Clinical Inducers and Noninducers of CYP3A4 with Plated Human Hepatocytes 2014 ·Drug Metabolism and Disposition ·George Zhang, (unknown), (unknown), R. J. H. Clark, (unknown), (unknown), Deqing Xiao, (unknown), Heidi J. Einolf, David M. Stresser	26
7	Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug–drug interaction to support regulatory submissions 2011 ·Xenobiotica ·Robert Elsby, (unknown), (unknown), David M. Stresser, (unknown), Pradeep Sharma, Dominic Surry	28
8	A Multi-Endpoint Evaluation of Cytochrome P450 1A2, 2B6 and 3A4 Induction Response in Human Hepatocyte Cultures After Treatment with β - Naphthoflavone, Phenobarbital and Rifampicin 2010 ·Drug Metabolism Letters ·George Zhang, (unknown), (unknown), Charles L. Crespi, David M. Stresser	26
9	Evaluation of Multiple in Vitro Systems for Assessment of CYP3A4 Induction in Drug Discovery: Human Hepatocytes, Pregnane X Receptor Reporter Gene, and Fa2N-4 and HepaRG Cells 2009 ·Drug Metabolism and Disposition ·Dermot F. McGinnity, George Zhang, Jane R. Kenny, Geraldine A. Hamilton, (unknown), (unknown), (unknown), Patrick Brassil, David M. Stresser, Robert J. Riley	64
10	Differential Time- and NADPH-Dependent Inhibition of CYP2C19 by Enantiomers of Fluoxetine 2009 ·Drug Metabolism and Disposition ·David M. Stresser, (unknown), Elke S. Perloff, (unknown), Charles L. Crespi, Andre Dandeneau, (unknown), Shangara S. Dehal	16
11	Validation of cytochrome P450 time-dependent inhibition assays: a two-time point IC₅₀shift approach facilitatesk_inactassay design 2009 ·Xenobiotica ·Elke S. Perloff, (unknown), Shangara S. Dehal, (unknown), (unknown), (unknown), Andre Dandeneau, (unknown), (unknown), (unknown), Charles L. Crespi, David M. Stresser	71
12	HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81 2006 ·Drug Metabolism and Disposition ·George Zhang, Shangara S. Dehal, (unknown), Jennifer Johnson, (unknown), Andrew P. Blanchard, R. J. H. Clark, Charles L. Crespi, David M. Stresser, (unknown)	34
13	David Kupfer: A Career Retrospective 2006 ·Drug Metabolism Reviews ·David M. Stresser	1
14	HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE 2004 ·Drug Metabolism and Disposition ·David M. Stresser, (unknown), (unknown), (unknown), Andrew P. Blanchard, Raman Sharma, Andre Dandeneau, (unknown), Stephanie D. Turner, John C. L. Erve, Christopher Patten, Shangara S. Dehal, Charles L. Crespi	115
15	In vitro and pharmacophore insights into CYP3A enzymes 2003 ·Trends in Pharmacological Sciences ·Sean Ekins, David M. Stresser, J. Andrew Williams	121
16	Concurrent Flavin-Containing Monooxygenase Down Regulation and Cytochrome P450 Induction by Dietary Indoles in the Rat: Implication for Drug-Drug Interactions 2001 ·Advances in experimental medicine and biology ·D E Williams, (unknown), (unknown), David M. Stresser, Shangara S. Dehal, David Kupfer	42
17	Fluorometric High‐Throughput Screening for Inhibitors of Cytochrome P450 2000 ·Annals of the New York Academy of Sciences ·Vaughn P. Miller, David M. Stresser, (unknown), Stephanie D. Turner, Charles L. Crespi	70
18	Influence of β-Naphthoflavone and Methoxychlor Pretreatment on the Biotransformation and Estrogenic Activity of Methoxychlor in Channel Catfish (Ictalurus punctatus) 1997 ·Toxicology and Applied Pharmacology ·Daniel Schlenk, David M. Stresser, (unknown), Alison Nimrod, William H. Benson	36
19	Induction of Hepatic CYPIA by Indole-3-Carbinol in Protection Against Aflatoxin B1 Hepatocarcinogenesis in Rainbow Trout 1995 ·Food and Chemical Toxicology ·Naoko Takahashi, David M. Stresser, David E. Williams, G.S. Bailey	38
20	The anticarcinogen 3,3′‐diindolylmethane is an inhibitor of cytochrome P‐450 1995 ·Journal of Biochemical Toxicology ·David M. Stresser, G.S. Bailey, David E. Williams, Leonard F. Bjeldanes	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact